Search

Great new opportunity for the YoungEHA community!

Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee

The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Other COVID-19 Resources

Safety of COVID-19 vaccines – April updates

ECDC and EMA issue advice on fourth doses of mRNA COVID-19 vaccines

EMA recommends authorisation of COVID-19 medicine Evusheld

EMA recommends authorisation of booster doses of Comirnaty from 12 years of age

EMA recommends approval of Spikevax…

Read more

Honorary Awards

EHA honors leaders in hematological research through the José Carreras Award (since 1999) and outstanding physicians and scientists by means of the Jean Bernard Lifetime Achievement Award (since 2008).

Read more

The glamorous life of parenthood and medicine

The glamorous life of parenthood and medicine

By Ana Zelić Kerep, MD (YoungEHA Ambassador)

Is it possible to have it all – the career, the family, good health, and sanity? Is it possible to give all of yourself to work and still…

Read more